Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
"OFFICIAL PARTNER RESMI FIFA WORLD CUP 2018 RUSSIA!
Ayo segera bergabung bersama kami dan Dukung Negara Jagoan kamu hanya di BOLAVITA
Info Lebih Lanjut Bisa Hub CS kami :
wechat : bolavita
whatup : 6281377055002
BBM: BOLAVITA(NEW)"
"Ayok Bergabung Bersama Kami Dan Dapatkan Bonus Di Bulan Suci Ramahdan Idul Fitri
Kerahasiaan Anda Terjamin
100% Terpercaya,Dan Terbaik Tidak Diragukan Lagi.
Karena sudah Lebih Dari Ribuan Member kami Yang sudah Membuktikan nya...
? WA: 082312256064
? BBM : D88B0154"
